基于CYP2C19表型的埃斯基塔洛普拉姆人群药理动力学和补救策略
Xin Liu1, Gehang Ju1, Xinyi Huang1
1Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China; Hunan Key Laboratory of Pharmacogenetics, Xiangya Hospital, Institute of Clinical Pharmacology, Central South University, Changsha, China; Hunan Key Laboratory for Bioanalysis of Complex Matrix Samples, Changsha Duxact Biotech Co., Ltd., Changsha, China.
这项研究在中国人群中开发了埃斯基塔洛普拉姆 (SCIT) 的种群药动力学模型,确定CYP2C19表型和体重是关键因素. 它提出了个性化剂量策略,以管理不坚持和优化SCIT治疗.
科学领域:
- 药理动力学 药理动力学
- 药物基因组学 药物基因组学
- 药物新陈代谢 药物新陈代谢
背景情况:
- 细胞染色体P450 2C19 (CYP2C19) 显著影响埃斯基塔洛普拉姆 (SCIT) 暴露,但研究结果因研究而异.
- 对于有效治疗,需要对中国人口中SCIT倾向的强有力的理解.
研究的目的:
- 为SCIT在中国人群中开发一个人群药理动力学 (popPK) 模型.
- 模拟非坚持情景,并为SCIT治疗提出个性化剂量策略.
主要方法:
- 应用了非线性混合效应建模,使用来自中国两项生物等价性研究的数据.
- 蒙特卡洛模拟被用来探索不坚持和确定最佳的剂量调整.
主要成果:
- 一个带有过境吸收和线性消除的单间模型最好地描述了SCIT数据.
- 鉴定出CYP2C19表型和体重是影响SCIT暴露的显著共变量.
- 根据CYP2C19基因型和延迟持续时间,提供了管理延迟或遗漏剂量的具体建议.
结论:
- 该研究强调了患者特异性因素的重要性,如CYP2C19基因型,在个性化埃斯基塔洛普拉姆治疗中.
- 开发的popPK模型为精确剂量和管理SCIT不遵守提供了一个框架.
更多相关视频
10:44Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
Published on: March 28, 2017
06:14Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
Published on: October 15, 2017
相关概念视频
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
A study on guinea pigs examined the...
Antidepressant Drugs: Overview
Analysis of Population Pharmacokinetic Data
Hepatic Drug Clearance: Role of Transporters
Antidepressant Drugs: MAOIs and Other Agents
Factors Affecting Drug Biotransformation: Biological
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
